

Appl. No. 10/606,632
Reply to Office Action of January 25, 2006

REMARKS/ARGUMENTS

Claim 6 is indicated to be allowable if rewritten in independent form. Claim 6 has been rewritten and allowance thereof is requested.

Claim 2 has been canceled and replaced with new claim 22, primarily as a clerical convenience. This is because the recitation in the last 30 or so pages of claim 22 is being deleted and clerically it would require reproducing and then crossing out the text thereof. New claim 22 is the first several pages of claim 2 wherein each of the named insulin sensitizers is retained and the insulin sensitizers which were defined by formula (Ia), etc. have now been deleted.

New claims have been added to claim each of the insulin sensitizers separately.

Claims 2, 4 and 7 were rejected under 35 USC 112, first paragraph, for a lack of enablement of a pharmaceutical composition containing amiloride in combination with the huge number of insulin sensitizers required in claim 2 or the diuretics which were within the scope of claim 4. To reduce

Appl. No. 10/606,632
Reply to Office Action of January 25, 2006


these issues, as noted above, the claims have been restricted to certain named insulin sensitizers. As evidence that these sensitizers are known to be active, there is annexed hereto copies of pages from an investigational drugs data base.

In view of the above, it is submitted that the scope of the claims as now presented, is supported by the specification and by the knowledge of persons of ordinary skill in the art.

Withdrawal of the rejections and allowance of the application is respectfully requested.

Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Ave., 16th Floor
New York, NY 10001-7708
Tel. No. (212) 319-4900
Fax No.: (212) 319-5101
MJC/ld

Respectfully submitted,


MARSHALL J. CHICK
Reg. No. 26,853

Enc.: Copies of pages from an investigational drugs data base
(13 pages)